Equifax
EFX
$158.87
-1.43%
Equifax, Incorporated is one of the three dominant U.S. credit bureaus, operating alongside Experian and TransUnion, and provides credit reports, credit scores, and decisioning analytics that underpin lenders' credit decisions nationwide. Beyond its core consumer credit franchise, roughly 40% of revenue comes from Workforce Solutions — income verification and employer HR services — while approximately 25% of revenue is generated outside the United States, giving the company a diversified, data-monetization platform identity rather than a pure-play credit reporting utility. The current investor narrative is dominated by a sharp divergence between operating execution and stock performance: revenue growth has reaccelerated to double digits (Q1 2026 revenue of $1.65 billion, up 14.35% year over year), yet the shares have fallen roughly 35% over the past year as investors fret over consumer credit health, mortgage origination weakness, and the sustainability of Workforce Solutions growth tied to government and employer verification demand. The debate now centers on whether Equifax's data assets and new-product innovation (cloud-native platform, verification services) can offset cyclical pressure on credit inquiry volumes, with the stock's steep underperformance versus the S&P 500 making it a contested value-versus-value-trap case.…
EFX
Equifax
$158.87
Related headlines
Investment Opinion: Should I buy EFX Today?
We assign a Hold rating on EFX, balancing the company's strong revenue growth and discounted forward valuation against its high leverage, weak current ratio, and uncertain earnings recovery. The analyst consensus is Buy with an average target of $214.95, implying 27.2% upside, but the stock's 35% one-year decline and 51.3 percentage point underperformance versus the S&P 500 suggest that the market is pricing in significant risks that may not be fully reflected in the consensus.
The supporting evidence for a Hold is mixed. On the positive side, revenue grew 14.35% YoY in Q1 2026, free cash flow is robust at $1.14 billion, and the forward PE of 16.6x is well below the trailing PE of 40.5x, indicating expected earnings growth. However, the trailing PE remains high, the current ratio of 0.60 is a liquidity concern, and debt-to-equity of 1.11 is elevated. The dividend yield of 0.87% is modest, and the payout ratio of 35.3% is sustainable but not a major attraction. Compared to peers, Equifax's valuation is not obviously cheap on trailing metrics, but the forward multiple suggests a potential value opportunity if earnings recover as expected.
The biggest risks that could invalidate the thesis are a deterioration in consumer credit health, a slowdown in mortgage originations, and competitive pressures from AI-driven fintechs. The rating would upgrade to Buy if forward EPS estimates are met or exceeded and the current ratio improves above 1.0, or if the stock drops below $150 (near the 52-week low) while fundamentals remain intact. It would downgrade to Sell if revenue growth decelerates below 8% or if free cash flow turns negative. Relative to its own history and peers, EFX appears fairly valued on a forward basis but overvalued on trailing metrics, suggesting that the market is already pricing in a recovery.
Sign up to view all
EFX 12-Month Price Forecast
Equifax presents a classic value-versus-value-trap dilemma. The company's revenue is growing at a healthy 14.35% clip, and the forward valuation of 16.6x earnings is attractive if the expected EPS recovery to $13.50 materializes. However, the trailing PE of 40.5x and the weak balance sheet metrics (current ratio 0.60, D/E 1.11) suggest that the margin of safety is thin. The analyst community remains bullish, but the stock's 35% one-year decline indicates that the market is skeptical. We would upgrade to bullish if the company demonstrates two consecutive quarters of EPS growth toward the forward estimate and improves its current ratio above 1.0. We would downgrade to bearish if revenue growth falls below 8% or if free cash flow declines significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Equifax's 12-month outlook, with a consensus price target around $214.95 and implied upside of +35.3% versus the current price.
Average Target
$214.95
0 analysts
Implied Upside
+35.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$179 - $245
Analyst target range
Bulls vs Bears: EFX Investment Factors
The bull case rests on Equifax's reaccelerating revenue growth (14.35% YoY), strong free cash flow ($1.14 billion), and a compelling forward valuation (16.6x forward PE) that suggests the market is overly pessimistic. The bear case is anchored in the stock's 35% one-year decline, a still-rich trailing PE of 40.5x, high leverage (D/E 1.11), and a weak current ratio (0.60) that leaves little margin for error. Currently, the bear evidence appears stronger on price action and balance sheet metrics, but the bull case gains credibility from the analyst consensus (Buy, $214.95 target) and the forward earnings recovery implied by the gap between trailing and forward PE. The single most important tension is whether the expected EPS recovery to $13.50 materializes; if it does, the stock is deeply undervalued, but if consumer credit deteriorates further, the forward estimates could be revised sharply lower, turning the value case into a value trap.
Bullish
- Revenue Growth Reaccelerating to 14.35%: Q1 2026 revenue of $1.649 billion grew 14.35% year over year, accelerating from the 9.8% growth implied by Q1 2025 revenue of $1.442 billion. This is the strongest top-line expansion in recent quarters and suggests Equifax's new-product innovation and pricing power are offsetting cyclical pressure on credit inquiry volumes.
- Analyst Consensus Buy with 27% Upside: 21 analysts rate EFX a Buy (recommendation mean 1.67) with an average target price of $214.95, implying 27.2% upside from the current $169.00. The low target of $179.00 is still 5.9% above the current price, indicating that even the most cautious analyst sees limited downside from here.
- Forward PE of 16.6x Is Historically Cheap: The forward PE of 16.61x is well below the trailing PE of 40.48x, reflecting expected EPS of $13.50 in the forward year versus trailing EPS of $4.17. This compression implies the market is pricing in a significant earnings recovery that has not yet been reflected in the stock price.
- Strong Free Cash Flow Generation: EFX generated $1.139 billion in trailing free cash flow, which covers its dividend payout (payout ratio 35.3%) more than twice over and provides ample capacity for debt reduction or share repurchases. This cash generation underpins the 0.87% dividend yield and supports the investment-grade balance sheet.
Bearish
- Stock Down 35% in One Year, Massive Underperformance: EFX has fallen 35.06% over the past year while the S&P 500 gained 16.22%, a relative underperformance of 51.28 percentage points. This severe divergence from the market suggests deep investor skepticism about the sustainability of earnings growth and the health of the consumer credit cycle.
- Trailing PE of 40.5x Is Extremely Rich: Despite the stock's decline, the trailing PE remains elevated at 40.48x, reflecting trailing EPS of just $4.17. The market is paying a premium multiple for depressed earnings, and if the expected recovery does not materialize, the stock could face further multiple compression.
- High Debt and Weak Current Ratio: Debt-to-equity stands at 1.11, and the current ratio is only 0.60, indicating that current liabilities exceed current assets by a wide margin. This financial leverage amplifies risk in a rising-rate environment and limits flexibility if credit conditions deteriorate.
- Short Interest Elevated at 7.24 Days to Cover: The short ratio of 7.24 suggests that bearish positioning is significant, with short sellers betting against a near-term recovery. While this can fuel a squeeze, it also signals that a substantial cohort of investors expects continued weakness in credit demand and mortgage originations.
EFX Technical Analysis
Beta
1.30
1.30x market volatility
Max Drawdown
-42.1%
Largest decline past year
52-Week Range
$151-$262
Price range past year
Annual Return
-39.1%
Cumulative gain past year
| Period | EFX Return | S&P 500 |
|---|---|---|
| 1m | -17.3% | -1.0% |
| 3m | +3.2% | +2.0% |
| 6m | -10.8% | +17.4% |
| 1y | -39.1% | +15.0% |
| ytd | -25.8% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EFX Fundamental Analysis
Quarterly Revenue
$1.6B
2026-03
Revenue YoY Growth
+14.3%
YoY Comparison
Gross Margin
53.5%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EFX Overvalued?
PE
40.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 28x~73x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.3x
Enterprise Value Multiple
Investment Risk Disclosure
Equifax faces significant financial and operational risks. The company carries a debt-to-equity ratio of 1.11 and a current ratio of just 0.60, meaning current liabilities exceed current assets by a substantial margin, which could strain liquidity if credit markets tighten. Additionally, trailing EPS of $4.17 is modest relative to the forward estimate of $13.50, implying that the entire investment thesis hinges on a dramatic earnings recovery; any shortfall in that recovery would leave the stock vulnerable. Furthermore, approximately 40% of revenue comes from Workforce Solutions, which is tied to government and employer verification demand—a segment that could face regulatory or budgetary pressures, while the core credit reporting business remains cyclical and sensitive to mortgage origination volumes.
Market and competitive risks are also pronounced. EFX trades at a trailing PE of 40.5x and a price-to-book of 5.81x, both elevated relative to historical norms, leaving little room for disappointment. The stock's beta of 1.305 means it is 30.5% more volatile than the market, so any macro-driven sell-off would likely hit EFX harder than the broader indices. Competition from Experian and TransUnion, as well as emerging fintech players like Upstart that are leveraging AI for credit decisioning, could erode Equifax's pricing power and market share over time. Recent news highlighting Upstart's AI-driven loan growth underscores the threat of technological disruption in the credit ecosystem.
In a worst-case scenario, a U.S. recession would trigger a surge in unemployment, a collapse in mortgage originations, and a sharp increase in credit defaults, reducing demand for credit reports and verification services. This could cause forward EPS estimates to be revised down toward the trailing level of $4.17, and the stock could retest its 52-week low of $150.75, representing a 10.8% decline from the current $169.00. If the bear case target of $179.00 is breached and sentiment worsens, a drop to the 52-week low would be a realistic downside, and in a severe scenario, the stock could fall further to the $140–150 range, implying a loss of 11–17% from current levels. The maximum drawdown over the past year was 42.08%, illustrating the potential magnitude of losses in adverse conditions.
FAQ
The key risks for EFX include financial, competitive, macro, and company-specific factors. Financially, the debt-to-equity of 1.11 and current ratio of 0.60 indicate high leverage and potential liquidity strain. Competitively, AI-driven fintechs like Upstart are challenging traditional credit bureaus with faster, data-driven lending models. Macroeconomic risks include a potential recession that would reduce credit inquiry volumes and increase defaults, and the stock's beta of 1.305 makes it more volatile than the market. Company-specific risks include regulatory scrutiny over data privacy and the sustainability of Workforce Solutions growth, which accounts for 40% of revenue. These risks are ranked from highest to lowest severity: macro recession, competitive disruption, financial leverage, and regulatory changes.
Our 12-month forecast for EFX includes three scenarios. The bull case (30% probability) targets $215–$245, driven by a soft economic landing, strong revenue growth, and EPS meeting the $13.50 estimate. The base case (50% probability) targets $180–$215, assuming moderate growth and stable credit conditions, with the stock gradually rising toward the analyst average of $214.95. The bear case (20% probability) targets $150–$179, reflecting a recession, declining credit demand, and EPS downgrades. The most likely scenario is the base case, which assumes that Equifax meets analyst estimates and the stock re-rates modestly. The key assumption is that consumer credit quality remains stable and mortgage originations do not collapse.
EFX appears overvalued on trailing metrics but potentially undervalued on forward estimates. The trailing PE of 40.5x is well above the market average, reflecting depressed trailing EPS of $4.17. However, the forward PE of 16.6x, based on estimated EPS of $13.50, is below the broader market and suggests that the stock is pricing in a significant earnings recovery. The price-to-book ratio of 5.81x is also elevated, indicating that the market values Equifax's intangible data assets highly. Relative to its own history, the forward PE is near the lower end of its range, which could signal a value opportunity if the recovery materializes. The market is currently pricing in a moderate probability of that recovery, leaving room for upside if estimates are met.
EFX is a good buy for investors with a high risk tolerance and a long-term horizon, but it is not without significant risks. The stock trades at $169, with a forward PE of 16.6x and analyst average target of $214.95, implying 27.2% upside. However, the trailing PE of 40.5x and weak current ratio of 0.60 suggest that the company's earnings recovery is not guaranteed. The 35% one-year decline and 51.3 percentage point underperformance versus the S&P 500 indicate that the market is pricing in substantial headwinds. For value-oriented investors willing to wait for a consumer credit recovery, EFX could be attractive, but conservative investors may want to wait for clearer signs of fundamental improvement.
EFX is more suitable for long-term investment than short-term trading. The company is in a mature growth stage, with a beta of 1.305 indicating higher volatility than the market, which makes short-term price movements unpredictable. The dividend yield of 0.87% is modest, so income is not a primary attraction. Earnings visibility is moderate, with analyst estimates ranging from $12.90 to $14.24 for the forward year, but the wide range reflects uncertainty. A long-term investor with a 3–5 year horizon could benefit from the expected earnings recovery and the company's dominant market position. Short-term traders might find opportunities around earnings announcements, but the high short interest (7.24 days to cover) could lead to sharp squeezes. We recommend a minimum holding period of 2–3 years to allow the credit cycle to normalize.